For More Information Contact:
Amy Rickard
Cleveland Medical Devices Inc.
Phone: 216.791.6720
arickard@clevemed.com
www.CleveMed.com
FOR IMMEDIATE RELEASE
CLEVEMED AWARDED $194,000 NIH GRANT TO BEGIN DEVELOPMENT OF ASSISTIVE TECHNOLOGY COMMUNICATION DEVICE FOR PATIENTS WITH LOCKED-IN SYNDROME
CLEVELAND, OHIO, December 28, 2006 -
Cleveland Medical Devices Inc. (CleveMed) has been awarded a $194,000 Phase I grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to begin the development of an assistive technology (AT) device to provide a method of communication for people with locked-in syndrome.
Locked-in syndrome, often found in patients of advanced stage Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), often causes complete paralysis of all voluntary muscles in the body. People with this disorder are completely conscious, have all feeling, and are able to process thoughts, but they cannot move or communicate because of complete paralysis of nearly all of their voluntary muscles. CleveMed's device, "
The
ALS
Locked-In
COmmunicato
R, or
TALCOR (pronounced "TALKER"), will be a 4-mode communication aid for people with this disability. The primary method will use Electroencephalography (EEG) signals as a means for exchanging information between the brain and the device through a Brain Computer Interface (BCI).
According to Robert N. Schmidt, company Chairman and grant principal investigator, "this program will provide a simple device to take standard assistive technology to the next level with Biometric Interfaces."
About CleveMed
CleveMed was founded with the goal of developing innovative telemetry devices for a variety of medical
applications. Today, CleveMed is developing and pioneering the use of novel wireless monitoring
systems for high growth neurology and rehabilitation applications, including
movement disorders,
sleep
disorders and brain monitoring. Through these innovations, CleveMed has developed a growing range of
products that address the needs of the
medical,
research and
academic communities. For more
information, please visit
www.CleveMed.com